Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 22, 2019 08:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Announces Clinical Development Plans for Oral Brilacidin for Inflammatory Bowel Disease

BEVERLY, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to announce plans to initiate in 2019 a...
January 17, 2019 09:12 ET | Source: Indoor Harvest Corp

Indoor Harvest Corp to Form Cannabis Joint Venture, Provides Guidance for 2019, and to Host Special Meeting of Shareholders

HOUSTON, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Indoor Harvest Corp (OTCQB: INQD), is a precision agriculture technology company, focused on producing bio-pharma grade Cannabis for the wholesale and...
January 14, 2019 08:00 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Completes Gastric Fluid Testing of Brilacidin Supporting Development of an Oral Dosage Form to Treat Inflammatory Bowel Disease

BEVERLY, Mass., Jan. 14, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders the Company has...
January 07, 2019 15:42 ET | Source: Generex Biotechnology Corp.

Generex Biotechnology Introduces Treatment Alternative to $6 Billion Ulcerative Colitis Surgery Market

Announces closing of 51% acquisition of regenerative medicine company Regentys™Regentys Extracellular Matrix Hydrogel for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases ...
January 07, 2019 04:00 ET | Source: Vital Therapies, Inc.

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

– Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets – – Lead Program, IMU-838, an...
December 17, 2018 08:00 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals Plans to Commence the First Ever Phase 3 Registration Trial in Celiac Disease in 1H 2019 and Announce Top-line NASH Data with Drug Combinations by EASL 2019

Preliminary top-line data from the alcoholic steatohepatitis (ASH) collaboration with Massachusetts General Hospital shows positive effect of larazotide on ethanol-induced permeability in vitro ...
December 17, 2018 07:00 ET | Source: Shire plc

FDA approves Shire’s Motegrity™ (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation (CIC)

Intended for U.S. Audience FDA approves Shire’s Motegrity™ (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation (CIC) Unlike other prescription...
December 12, 2018 07:50 ET | Source: Research and Markets

Global Ostomy Care Market 2018-2024 - Rising Incidence of Inflammatory Bowel Diseases (IBD) & Crohn's Disease Bodes Well for the Market

Dublin, Dec. 12, 2018 (GLOBE NEWSWIRE) -- The "Global Ostomy Care Market (By Type-Colostomy, Urostomy & Ileostomy; By Region-North America, Europe, Asia Pacific & Latin America) Market...
December 04, 2018 11:15 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals Enters into a Collaboration with Massachusetts General Hospital and Announces Capital Update for the Celiac Disease Clinical Program and its NASH Development Strategy on December 17, 2018

-- Announces collaboration in high unmet need Alcoholic Liver Diseases (ALD), including severe alcoholic hepatitis, with novel gut-specific, clinical-stage asset, larazotide acetate-- Investor update...
December 03, 2018 07:00 ET | Source: Breathtec Biomedical Inc.

Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease

VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...